A clinical study to assess the efficacy, safety, and tolerability of BMS-986278 in participants with idiopathic pulmonary fibrosis
Résumé de l'étude
In this clinical study, named IM027068, participants with IPF will be treated either with the study drug or with placebo twice daily. Neither you nor your study doctor knows which treatment you will receive. Participants may continue antifibrotic therapy for IPF with Nintedanib or Pirfenidone. The study consists of 2 parts: In Part 1, the first 60 participants with IPF will be enrolled so that a review committee can assess safety before Part 2 opens. In Part 2, the efficacy, safety, and tolerability of the study drug will be investigated in participants with IPF. Part 2 will include approximately 1125 participants. The study will last approximately 4 years in total.
(BASEC)
Intervention étudiée
The treatment period lasts from the visit date on Day 1 for the first participant until the end of treatment for the last participant, approximately 4 years (the individual study duration for a participant may range from at least 52 weeks to approximately 4 years, depending on when the last participant completes the visit at Week 52).
The study intervention consists of a blinded investigational product that is to be taken orally with liquid twice daily.
(BASEC)
Maladie en cours d'investigation
There remains a significant unmet need for a safe, well-tolerated, and effective therapy for idiopathic pulmonary fibrosis (IPF) that improves lung function, delays disease progression, and reduces mortality. BMS-986278 is an orally administered investigational product being developed for the treatment of patients with IPF and progressive pulmonary fibrosis (PPF). A clinical study in participants with pulmonary fibrosis has shown favorable safety and efficacy with BMS-986278 as a monotherapy and in participants on antifibrotic treatment.
(BASEC)
Patients with IPF aged ≥ 40 years at the time of signing the informed consent; IPF diagnosis within the last 7 years; Participants on Pirfenidone or Nintedanib must have received a stable dose for at least 90 days; Participants who are currently not receiving either Pirfenidone or Nintedanib must not have received either of these two medications within 28 days prior to screening. (BASEC)
Critères d'exclusion
History of stroke or ischemic attack within 3 months prior to the study; Significant heart disease within 6 months prior to the study (BASEC)
Lieu de l’étude
Bâle, Berne
(BASEC)
Sponsor
Bristol-Myers Squibb SA, Hinterbergstrasse 16, CH-6312 Steinhausen
(BASEC)
Contact pour plus d'informations sur l'étude
Personne de contact en Suisse
Prof. Dr. Katrin Hostettler Haack
+41 61 265 25 25
Katrin.Hostettler@clutterusb.chUniversitätsspital Basel, Pneumologie, Petersgraben 4, 4031 Basel
(BASEC)
Informations scientifiques
non disponible
Nom du comité d'éthique approbateur (pour les études multicentriques, uniquement le comité principal)
Ethikkommission Nordwest- und Zentralschweiz EKNZ
(BASEC)
Date d'approbation du comité d'éthique
31.08.2023
(BASEC)
Identifiant de l'essai ICTRP
non disponible
Titre officiel (approuvé par le comité d'éthique)
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants with Idiopathic Pulmonary Fibrosis (BASEC)
Titre académique
non disponible
Titre public
non disponible
Maladie en cours d'investigation
non disponible
Intervention étudiée
non disponible
Type d'essai
non disponible
Plan de l'étude
non disponible
Critères d'inclusion/exclusion
non disponible
non disponible
Critères d'évaluation principaux et secondaires
non disponible
non disponible
Date d'enregistrement
non disponible
Inclusion du premier participant
non disponible
Sponsors secondaires
non disponible
Contacts supplémentaires
non disponible
ID secondaires
non disponible
Résultats-Données individuelles des participants
non disponible
Informations complémentaires sur l'essai
non disponible
Résultats de l'essai
Résumé des résultats
non disponible
Lien vers les résultats dans le registre primaire
non disponible